Amneal Pharmaceuticals, Inc.
AMRX
株式のランク
#2940
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
株価
$19.78
時価総額
$6.32B
変化（1日）
2.15%
変化（1年）
93.12%
国
US
取引 Amneal Pharmaceuticals, Inc. (AMRX)
カテゴリー
Healthcare
Amneal Pharmaceuticals, Inc.（AMRX）の株式分割履歴
Amneal Pharmaceuticals, Inc.株（シンボル：AMRX）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 20, 2026に行われました。
Oct 20, 2026より前に購入されたAMRX株は、現在0AMRX株に相当します。
最新の株式分割はOct 20, 2026に行われました。
Oct 20, 2026より前に購入されたAMRX株は、現在0AMRX株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 提供された日付のデータは十分ではありません。 | |||
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 0 | - |
DE
|
|
| 0 | - |
DE
|
|
| 0 | - |
JP
|
|
| 0 | - |
CH
|
|
| 5 | x119 |
IN
|
